Related Experiment Video

Updated: Aug 20, 2025

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
07:44

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

7.6K

More than one route to render tumors resistant to cGAS/STING activation

Cherubin Manokaran1, Thomas M Roberts1, Yubao Wang1

  • 1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Departments of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.

Trends in Pharmacological Sciences
|November 22, 2022
PubMed

Insights

Stimulator of interferon genes (STING) activation shows promise for cancer therapy but faces clinical challenges. New research explains STING agonist failures in human tumors and suggests combination strategies to enhance efficacy.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Stimulator of interferon genes (STING) activation is a promising cancer immunotherapy strategy.
  • Clinical trials using STING agonists have yielded disappointing results in human tumor regression.

Purpose of the Study:

  • To elucidate the reasons behind the limited efficacy of STING agonists in human tumors.
  • To propose novel combinatorial therapeutic strategies to overcome STING-mediated protumor effects.

Main Methods:

  • Analysis of recent studies by Hong et al. and Li et al.
  • Investigating the mechanisms underlying STING agonist failure in clinical settings.
  • Developing theoretical frameworks for combination therapies targeting STING pathways.

Main Results:

  • Identified specific reasons for STING agonist non-response in human cancers.
  • Highlighted the protumorigenic roles of STING activation in certain contexts.
  • Proposed synergistic approaches combining STING agonists with other treatments.

Conclusions:

  • Understanding STING pathway intricacies is crucial for successful cancer treatment.
  • Combinatorial strategies are necessary to counteract STING-induced protumorigenic effects.
  • Future research should focus on personalized STING-targeted therapies for improved outcomes.
Keywords:
IL35IL6chromosome instabilityregulatory B cells

More Related Videos

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.8K
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
631
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K